DBV Technologies Logo

DBV Technologies

Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.

DBV | PA

Overview

Corporate Details

ISIN(s):
FR0010417345 (+3 more)
LEI:
969500PVBQFWQKVDMD80
Country:
France
Address:
107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON

Description

DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-11-24 07:30
DBV Technologies annonce des changements dans son équipe de direction
French 151.4 KB
2020-11-24 07:30
DBV Technologies Announces Leadership Changes
English 140.8 KB
2020-11-11 10:30
Information mensuelle relative au nombre total des droits de vote et d’actions …
French 96.8 KB
2020-11-11 10:30
Monthly information regarding the total number of voting rights and total numbe…
English 160.6 KB
2020-11-10 07:30
DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Pa…
English 254.7 KB
2020-11-10 07:30
DBV Technologies va présenter des données sur le mode d’administration du trait…
French 225.5 KB
2020-11-09 07:30
DBV Technologies invitée à présenter lors de prochaines conférences Investisseu…
French 178.0 KB
2020-11-02 07:30
DBV Technologies Announces Filing and Validation of Marketing Authorization App…
English 208.6 KB
2020-11-02 07:30
DBV Technologies annonce le dépôt et la validation d'une demande d'Autorisation…
French 204.1 KB
2020-10-30 06:30
DBV Technologies Reports September 30, 2020 Cash Position
English 430.7 KB
2020-10-30 06:30
DBV Technologies publie sa position de trésorerie au 30 septembre 2020
French 454.3 KB
2020-10-08 22:01
Information mensuelle relative au nombre total des droits de vote et d’actions …
French 96.7 KB
2020-10-08 22:01
Monthly information regarding the total number of voting rights and total numbe…
English 160.5 KB
2020-09-15 22:30
Monthly information regarding the total number of voting rights and  total numb…
English 160.4 KB
2020-09-15 22:30
Information mensuelle relative au nombre total des droits de vote et d’actions …
French 96.9 KB

Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DBV Technologies

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DBV Technologies via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-09 N/A Other Other 2,483,161 7,449,483.00 EUR

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.